Pharmaceutical manufacturers are reportedly under scrutiny as the Trump administration considers linking drug prices in the United States to lower prices paid in other developed countries. According to two sources from the industry, this potential policy shift is emerging as a central issue for the pharmaceutical sector. These discussions are anticipated to originate from the agency that oversees Medicare and Medicaid health programs, which could significantly impact pricing strategies across the industry.